Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

CyTOF Mass Cytometry for Click Proliferation Assays.

Tosevski V, Ulashchik E, Trovato A, Cappella P.

Curr Protoc Cytom. 2017 Jul 5;81:7.50.1-7.50.14. doi: 10.1002/cpcy.25.

PMID:
28678421
2.

FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.

Tassi RA, Todeschini P, Siegel ER, Calza S, Cappella P, Ardighieri L, Cadei M, Bugatti M, Romani C, Bandiera E, Zanotti L, Tassone L, Guarino D, Santonocito C, Capoluongo ED, Beltrame L, Erba E, Marchini S, D'Incalci M, Donzelli C, Santin AD, Pecorelli S, Sartori E, Bignotti E, Odicino F, Ravaggi A.

J Exp Clin Cancer Res. 2017 May 8;36(1):63. doi: 10.1186/s13046-017-0536-y.

3.

A Novel High-Content Immunofluorescence Assay as a Tool to Identify at the Single Cell Level γ-Globin Inducing Compounds.

Durlak M, Fugazza C, Elangovan S, Marini MG, Marongiu MF, Moi P, Fraietta I, Cappella P, Barbarani G, Font-Monclus I, Mauri M, Ottolenghi S, Gasparri F, Ronchi A.

PLoS One. 2015 Oct 28;10(10):e0141083. doi: 10.1371/journal.pone.0141083. eCollection 2015.

4.

Cell Proliferation Method: Click Chemistry Based on BrdU Coupling for Multiplex Antibody Staining.

Cappella P, Gasparri F, Pulici M, Moll J.

Curr Protoc Cytom. 2015 Apr 1;72:7.34.1-7.34.17. doi: 10.1002/0471142956.cy0734s72.

PMID:
25827484
5.

Application of click chemistry conditions for 5-bromo-2'-deoxyuridine determination through Fenton and related reactions.

Cappella P, Pulici M, Gasparri F.

Curr Protoc Cytom. 2015 Jan 5;71:7.43.1-7.43.17. doi: 10.1002/0471142956.cy0743s71.

PMID:
25559225
6.

From "Click" to "Fenton" chemistry for 5-bromo-2'-deoxyuridine determination.

Cappella P, Giansanti V, Pulici M, Gasparri F.

Cytometry A. 2013 Nov;83(11):989-1000. doi: 10.1002/cyto.a.22343. Epub 2013 Aug 13.

7.

Highly multiplexed phenotypic imaging for cell proliferation studies.

Cappella P, Gasparri F.

J Biomol Screen. 2014 Jan;19(1):145-57. doi: 10.1177/1087057113495712. Epub 2013 Jul 29.

PMID:
23896684
8.

NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies.

Valsasina B, Beria I, Alli C, Alzani R, Avanzi N, Ballinari D, Cappella P, Caruso M, Casolaro A, Ciavolella A, Cucchi U, De Ponti A, Felder E, Fiorentini F, Galvani A, Gianellini LM, Giorgini ML, Isacchi A, Lansen J, Pesenti E, Rizzi S, Rocchetti M, Sola F, Moll J.

Mol Cancer Ther. 2012 Apr;11(4):1006-16. doi: 10.1158/1535-7163.MCT-11-0765. Epub 2012 Feb 7.

9.

5-(2-amino-pyrimidin-4-yl)-1H-pyrrole and 2-(2-amino-pyrimidin-4-yl)-1,5,6,7-tetrahydro-pyrrolo[3,2-c]pyridin-4-one derivatives as new classes of selective and orally available Polo-like kinase 1 inhibitors.

Caruso M, Valsasina B, Ballinari D, Bertrand J, Brasca MG, Caldarelli M, Cappella P, Fiorentini F, Gianellini LM, Scolaro A, Beria I.

Bioorg Med Chem Lett. 2012 Jan 1;22(1):96-101. doi: 10.1016/j.bmcl.2011.11.065. Epub 2011 Nov 23.

PMID:
22154349
10.

Transcriptional analysis of the Aurora inhibitor Danusertib leading to biomarker identification in TP53 wild type cells.

Bosotti R, Carpinelli P, Healy S, Locatelli G, Cappella P, Lanfrancone L, Calogero R, Moll J, Isacchi A.

Gene. 2012 Feb 25;494(2):202-8. doi: 10.1016/j.gene.2011.08.014. Epub 2011 Sep 2.

PMID:
21914463
11.

Miniaturizing bromodeoxyuridine incorporation enables the usage of flow cytometry for cell cycle analysis of adherent tissue culture cells for high throughput screening.

Cappella P, Giorgini ML, Ernestina Re C, Ubezio P, Ciomei M, Moll J.

Cytometry A. 2010 Oct;77(10):953-61. doi: 10.1002/cyto.a.20962. Epub 2010 Sep 8.

12.

Phosphorylation of TCTP as a marker for polo-like kinase-1 activity in vivo.

Cucchi U, Gianellini LM, De Ponti A, Sola F, Alzani R, Patton V, Pezzoni A, Troiani S, Saccardo MB, Rizzi S, Giorgini ML, Cappella P, Beria I, Valsasina B.

Anticancer Res. 2010 Dec;30(12):4973-85.

PMID:
21187478
13.

Targeting the mitotic checkpoint for cancer therapy with NMS-P715, an inhibitor of MPS1 kinase.

Colombo R, Caldarelli M, Mennecozzi M, Giorgini ML, Sola F, Cappella P, Perrera C, Depaolini SR, Rusconi L, Cucchi U, Avanzi N, Bertrand JA, Bossi RT, Pesenti E, Galvani A, Isacchi A, Colotta F, Donati D, Moll J.

Cancer Res. 2010 Dec 15;70(24):10255-64. doi: 10.1158/0008-5472.CAN-10-2101.

14.

In vivo imaging of early stage apoptosis by measuring real-time caspase-3/7 activation.

Scabini M, Stellari F, Cappella P, Rizzitano S, Texido G, Pesenti E.

Apoptosis. 2011 Feb;16(2):198-207. doi: 10.1007/s10495-010-0553-1.

PMID:
21082356
15.

Thieno[3,2-c]pyrazoles: a novel class of Aurora inhibitors with favorable antitumor activity.

Bindi S, Fancelli D, Alli C, Berta D, Bertrand JA, Cameron AD, Cappella P, Carpinelli P, Cervi G, Croci V, D'Anello M, Forte B, Giorgini ML, Marsiglio A, Moll J, Pesenti E, Pittalà V, Pulici M, Riccardi-Sirtori F, Roletto F, Soncini C, Storici P, Varasi M, Volpi D, Zugnoni P, Vianello P.

Bioorg Med Chem. 2010 Oct 1;18(19):7113-20. doi: 10.1016/j.bmc.2010.07.048. Epub 2010 Jul 25.

PMID:
20817473
16.

Identification of 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives as a new class of orally and selective Polo-like kinase 1 inhibitors.

Beria I, Ballinari D, Bertrand JA, Borghi D, Bossi RT, Brasca MG, Cappella P, Caruso M, Ceccarelli W, Ciavolella A, Cristiani C, Croci V, De Ponti A, Fachin G, Ferguson RD, Lansen J, Moll JK, Pesenti E, Posteri H, Perego R, Rocchetti M, Storici P, Volpi D, Valsasina B.

J Med Chem. 2010 May 13;53(9):3532-51. doi: 10.1021/jm901713n.

PMID:
20397705
17.

Identification of Myb-binding protein 1A (MYBBP1A) as a novel substrate for aurora B kinase.

Perrera C, Colombo R, Valsasina B, Carpinelli P, Troiani S, Modugno M, Gianellini L, Cappella P, Isacchi A, Moll J, Rusconi L.

J Biol Chem. 2010 Apr 16;285(16):11775-85. doi: 10.1074/jbc.M109.068312. Epub 2010 Feb 22.

18.

Quantitative assessment of the complex dynamics of G1, S, and G2-M checkpoint activities.

Ubezio P, Lupi M, Branduardi D, Cappella P, Cavallini E, Colombo V, Matera G, Natoli C, Tomasoni D, D'Incalci M.

Cancer Res. 2009 Jun 15;69(12):5234-40. doi: 10.1158/0008-5472.CAN-08-3911. Epub 2009 Jun 9.

19.

Cell proliferation method: click chemistry based on BrdU coupling for multiplex antibody staining.

Cappella P, Gasparri F, Pulici M, Moll J.

Curr Protoc Cytom. 2008 Jul;Chapter 7:Unit7.34. doi: 10.1002/0471142956.cy0734s45.

PMID:
18770651
20.
21.

PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer.

Carpinelli P, Ceruti R, Giorgini ML, Cappella P, Gianellini L, Croci V, Degrassi A, Texido G, Rocchetti M, Vianello P, Rusconi L, Storici P, Zugnoni P, Arrigoni C, Soncini C, Alli C, Patton V, Marsiglio A, Ballinari D, Pesenti E, Fancelli D, Moll J.

Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3158-68.

22.

1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile.

Fancelli D, Moll J, Varasi M, Bravo R, Artico R, Berta D, Bindi S, Cameron A, Candiani I, Cappella P, Carpinelli P, Croci W, Forte B, Giorgini ML, Klapwijk J, Marsiglio A, Pesenti E, Rocchetti M, Roletto F, Severino D, Soncini C, Storici P, Tonani R, Zugnoni P, Vianello P.

J Med Chem. 2006 Nov 30;49(24):7247-51.

PMID:
17125279
23.

Multiparametric cell cycle analysis by automated microscopy.

Gasparri F, Cappella P, Galvani A.

J Biomol Screen. 2006 Sep;11(6):586-98. Epub 2006 Jul 14.

PMID:
16844964
24.

PHA-680632, a novel Aurora kinase inhibitor with potent antitumoral activity.

Soncini C, Carpinelli P, Gianellini L, Fancelli D, Vianello P, Rusconi L, Storici P, Zugnoni P, Pesenti E, Croci V, Ceruti R, Giorgini ML, Cappella P, Ballinari D, Sola F, Varasi M, Bravo R, Moll J.

Clin Cancer Res. 2006 Jul 1;12(13):4080-9.

25.

Interpreting cell cycle effects of drugs: the case of melphalan.

Lupi M, Cappella P, Matera G, Natoli C, Ubezio P.

Cancer Chemother Pharmacol. 2006 Apr;57(4):443-57. Epub 2005 Sep 30.

PMID:
16195878
26.

Potent and selective Aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibition.

Fancelli D, Berta D, Bindi S, Cameron A, Cappella P, Carpinelli P, Catana C, Forte B, Giordano P, Giorgini ML, Mantegani S, Marsiglio A, Meroni M, Moll J, Pittalà V, Roletto F, Severino D, Soncini C, Storici P, Tonani R, Varasi M, Vulpetti A, Vianello P.

J Med Chem. 2005 Apr 21;48(8):3080-4.

PMID:
15828847
27.

Cell cycle effects of gemcitabine.

Cappella P, Tomasoni D, Faretta M, Lupi M, Montalenti F, Viale F, Banzato F, D'Incalci M, Ubezio P.

Int J Cancer. 2001 Aug 1;93(3):401-8.

28.

Measuring the complexity of cell cycle arrest and killing of drugs: kinetics of phase-specific effects induced by taxol.

Sena G, Onado C, Cappella P, Montalenti F, Ubezio P.

Cytometry. 1999 Oct 1;37(2):113-24.

PMID:
10486523
29.

Characterization of cyclin B1 expression in human cancer cell lines by a new three-parameter BrdUrd/cyclin B1/DNA analysis.

Faretta M, Bergamaschi D, Taverna S, Ronzoni S, Pantarotto M, Mascellani E, Cappella P, Ubezio P, Erba E.

Cytometry. 1998 Jan 1;31(1):53-9.

PMID:
9450525
30.

Time- and dose-dependence of DNA fragmentation induced by anticancer agents: a flow cytometric study.

Cappella P, Onado C, Sena G, Montalenti F, Spinelli L, Ubezio P.

Eur J Histochem. 1997;41 Suppl 2:67-8. No abstract available.

PMID:
9859787

Supplemental Content

Loading ...
Support Center